PD173074

Licensed by Pfizer Catalog No.S1264

PD173074 Chemical Structure

Molecular Weight(MW): 523.67

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Size Price Stock Quantity  
In DMSO USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 27 Publications

7 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331(6019), 912-6. PD173074 purchased from Selleck.

    Inhibition of FGFR signaling pathway by FGFR inhibitor PD173074 in mouse xenograft tumors. Bladder cancer SW780 cells were implanted in mice and treated with PD173074 after tumor formation as shown in B. Protein lysates of tumor tissues were prepared and immunoblotted with antibodies against phospho-ERK1/2, pan-ERK1/2, and γ-tubulin.

    Cancer Discov 2013 3(6), 636-47. PD173074 purchased from Selleck.

  • FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.

    Hepatology 2014 59(4) ,1427-34. PD173074 purchased from Selleck.

    The level of p-FRS2 was examined in the uterine sections of Msx1f/fMsx2f/f (upper panel) and Msx1d/dMsx2d/d (lower panel) mice on day 4 of pregnancy by immunohistochemistry. Magnification: a and d: 10 x, b and e: 20 x, c and f: 40x. FGFR-specific inhibitor PD173074 was applied to one uterine horn of Msx1d/dMsx2d/d (n = 3) mice on day 3 of pregnancy. The other horn served as vehicle-treated control. Uterine horns were collected on day 4 morning and sections were subjected to immunohistochemistry to detect p-FRS2, Ki67, and Muc-1.

    PLoS Genet 2012 8(2), e1002500. PD173074 purchased from Selleck.

  • Cells were incubated with DMSO control, 10 uM TGFBR inhibitor or 10 uM FGFR inhibitor PD173074 for 1 h. Cells were fixed, labeled with anti-GM130 (red) and analyzed by confocal microscopy. Images were analyzed using Image J (n = 3 experiments, >100 cells per condition). Scale bars, 10 uM.

    J Cell Sci 2014 10.1242/jcs.159608. PD173074 purchased from Selleck.

    Effects of antagonists for RAGE (FPS-ZM), TLR-4 (TAK-242) and FGFR1 (PD and BGJ) on the S100B-induced alterations in glucose metabolism in L6 cells treated for 6 h. (A) Effects of FPS-ZM, (B) TAK-242 and (C) PD and BGJ on the S100B inhibition of glucose consumption.

    Am J Physiol Endocrinol Metab, 2017, 312(6):E471-E481. PD173074 purchased from Selleck.

  • Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 ℃ for 48 h, and the appearance of the mature protein, band C, monitored by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle- alone control, 27℃ represents temperature rescue of F508-CFTR at 27℃, 37℃ represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.

    Biochem Bioph Res Co 2012 11(9), 745-57. PD173074 purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 M4fpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEGyNlUh|ryP MVXTRW5ITVJ?
KG-1 M1Ltd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEWxNlkh|ryP NWjiZ206W0GQR1XS
MFM-223 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WzSWlEPTB;MD6yNVU4PiEQvF2= MY\TRW5ITVJ?
EoL-1-cell MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLqZ5FUUUN3ME2wMlMzQTh2IN88US=> MnTnV2FPT0WU
ECC10 NFe2OWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTQdZV2UUN3ME2wMlM{QDl6IN88US=> NYDUU5NwW0GQR1XS
H-EMC-SS NGHxR|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTQTWM2OD1yLkO0O|E2KM7:TR?= MkHtV2FPT0WU
AN3-CA NHTadYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rNPGlEPTB;MD60NFE{OyEQvF2= NH\XPFdUSU6JRWK=
HuO-3N1 M4TKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\hSVB{UUN3ME2wMlU1PjV|IN88US=> M3vuUnNCVkeHUh?=
RT-112 M4X4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jDcmlEPTB;MD61OFcxOSEQvF2= NYO0cGo1W0GQR1XS
NEC8 NWfOTXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TuT2lEPTB;MD61OlI5QSEQvF2= NEOyTYFUSU6JRWK=
D-263MG MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHodldKSzVyPUCuO|EyPTlizszN NWn1[4VQW0GQR1XS
SW962 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr1cG1rUUN3ME2wMlc5QTh6IN88US=> MYTTRW5ITVJ?
BV-173 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPTfIdKSzVyPUCuPFQ3OjNizszN MX;TRW5ITVJ?
MFE-280 M{PUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrjTWM2OD1yLki1PFczKM7:TR?= NGD2fJVUSU6JRWK=
HuH-7 NIjOZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SweWlEPTB;MT6yOFQ3PCEQvF2= MUHTRW5ITVJ?
RS4-11 NFPMd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX5OYlKSzVyPUGuN|M5QDZizszN MX\TRW5ITVJ?
DMS-114 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwM{[3N|ch|ryP NWfrbYdzW0GQR1XS
MSTO-211H M4fwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwNEezO|gh|ryP MYjTRW5ITVJ?
DU-145 NI\BSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz3XIJJUUN3ME2xMlU5OjF5IN88US=> Mk\BV2FPT0WU
A172 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwN{CzOVUh|ryP MWrTRW5ITVJ?
SBC-1 M2LmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJwMEm0JO69VQ>? MWDTRW5ITVJ?
H9 M2Lue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnNTlhMUUN3ME2yMlE1OzB4IN88US=> MX\TRW5ITVJ?
NCI-SNU-1 NVfSVINLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHocm9UUUN3ME2yMlE5Ozl2IN88US=> NWH0dpFPW0GQR1XS
NCI-H720 NFvIZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwMkGyPFMh|ryP NFT5T3hUSU6JRWK=
HCC2218 NGjr[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXKTWM2OD1{LkO3PVM6KM7:TR?= M{PlfXNCVkeHUh?=
G-401 MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwNEexPFkh|ryP M2f6VnNCVkeHUh?=
MPP-89 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jHXGlEPTB;Mj60PFM3PCEQvF2= NHXFbmRUSU6JRWK=
697 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX21Vmk6UUN3ME2yMlY2OzNzIN88US=> MXLTRW5ITVJ?
KARPAS-45 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwN{C3OFch|ryP NXnDUHhDW0GQR1XS
MG-63 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwOUSyOlIh|ryP MV\TRW5ITVJ?
NTERA-S-cl-D1 NUTqcnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H0[GlEPTB;Mz6wN|Q4OiEQvF2= M4ezVnNCVkeHUh?=
G-402 NXjSeXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTZOZFnUUN3ME2zMlEzPzJ5IN88US=> M4PCOnNCVkeHUh?=
NKM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTNwMUO1OlQh|ryP M3f2UnNCVkeHUh?=
RH-18 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\KZ2lEPTB;Mz6xPVU6QCEQvF2= M1XZS3NCVkeHUh?=
NCI-H1092 NIjDSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\kTWM2OD1|LkG5Olkh|ryP NH3pPWFUSU6JRWK=
RPMI-8226 M3PVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;ObmlEPTB;Mz6yN|Q1PyEQvF2= NVj5NZlnW0GQR1XS
GAMG M4ezW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrjc2J5UUN3ME2zMlQ3PTd4IN88US=> NVrMR|drW0GQR1XS
HH NUHZTo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwNEe2O|Yh|ryP MoHyV2FPT0WU
RO82-W-1 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXyT4lDUUN3ME2zMlQ6QDV3IN88US=> M4rFUnNCVkeHUh?=
CCRF-CEM NF7STYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\ueIp[UUN3ME2zMlUxPDh6IN88US=> NYq2NoN[W0GQR1XS
NBsusSR Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfaTWM2OD1|Lk[zPVY6KM7:TR?= NID3dphUSU6JRWK=
CHL-1 NH7wXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rkUWlEPTB;Mz62OVc6QSEQvF2= M2DaXHNCVkeHUh?=
LK-2 NV[3fIdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v1[WlEPTB;Mz62O|E{OyEQvF2= M1[3d3NCVkeHUh?=
Hs-578-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnKSHVKSzVyPUOuOlc5PzNizszN MWnTRW5ITVJ?
CTB-1 M{XTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnIeGtKSzVyPUOuPFAxPTFizszN NETCSGZUSU6JRWK=
ES5 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz5NYhkUUN3ME2zMlg{PjN5IN88US=> NES5PVBUSU6JRWK=
A204 M{n3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwOUKwO|Uh|ryP MXXTRW5ITVJ?
SW780 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTNwOUKyOFUh|ryP M3XuUXNCVkeHUh?=
EW-3 M{LEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDtTWM2OD1|Lkm4PVI{KM7:TR?= MlLVV2FPT0WU
A704 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwMki3NlMh|ryP M3\Ie3NCVkeHUh?=
LU-139 NInufodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTRwM{G1N|Qh|ryP MUDTRW5ITVJ?
CAL-72 NXHnRlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7GTWM2OD12LkSxO|Q3KM7:TR?= MnXWV2FPT0WU
D-336MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hoc2lEPTB;ND60OlgyPyEQvF2= Mn;qV2FPT0WU
LAMA-84 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfxXHgyUUN3ME20MlU{OzFizszN NWW1N4U{W0GQR1XS
GI-ME-N NH3n[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwNUS4NUDPxE1? MUDTRW5ITVJ?
KM-H2 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fNZmlEPTB;ND61OVIzOiEQvF2= M2\UXnNCVkeHUh?=
NCI-H209 M3L6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HKfGlEPTB;ND61PFI5OyEQvF2= NUW0bWVEW0GQR1XS
IGROV-1 NHuxNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTRwOEexOlgh|ryP MXvTRW5ITVJ?
L-363 M{HEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrsWHlHUUN3ME20Mlk3PjZ3IN88US=> M1vCNXNCVkeHUh?=
SK-MEL-3 NYTWfJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwMkSwOkDPxE1? MnXNV2FPT0WU
HuO9 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTVwM{i4OFMh|ryP NW\hNWRMW0GQR1XS
NOS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTVwN{K5Nlch|ryP MWDTRW5ITVJ?
NCI-H1770 NGfZcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTVwOUWwN|Ih|ryP NWm5[5VwW0GQR1XS
SF126 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKyTWM2OD14LkKxOFA3KM7:TR?= MlPZV2FPT0WU
ML-2 M1jId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTBNWlwUUN3ME22MlI1QTd5IN88US=> M37wdXNCVkeHUh?=
CHP-134 NILKUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO4dnRjUUN3ME22MlI2OTh{IN88US=> MYPTRW5ITVJ?
NCI-H1355 NV3sNmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPOdFV7UUN3ME22MlQyPzN|IN88US=> MUfTRW5ITVJ?
TE-12 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HtR2lEPTB;Nj63NlY4OSEQvF2= M3\MXXNCVkeHUh?=
A4-Fuk MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTZwN{OxOFIh|ryP M2TGb3NCVkeHUh?=
MV-4-11 NUK4VZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTZwN{[2NlYh|ryP NUPSTmV{W0GQR1XS
SK-UT-1 M3faVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwOUG3PFQh|ryP MUfTRW5ITVJ?
J-RT3-T3-5 NYnUNHNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnbGlEPTB;Nz6wO|c3PCEQvF2= MoDhV2FPT0WU
ME-180 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33rbWlEPTB;Nz6xNFQxPCEQvF2= MkX2V2FPT0WU
SK-MEL-28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrhTWM2OD15LkO3PFE6KM7:TR?= M3v4TnNCVkeHUh?=
HAL-01 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT5[HR{UUN3ME23MlQ5OzRzIN88US=> NFzBOZhUSU6JRWK=
ES8 M2\QXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHYe2RKSzVyPUeuOlk3OjZizszN M1niSHNCVkeHUh?=
DB Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDIUmtKSzVyPUiuNVE2ODRizszN NVnvb2NlW0GQR1XS
SK-NEP-1 NXPk[FRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TP[GlEPTB;OD60PFE1QSEQvF2= MWnTRW5ITVJ?
COR-L88 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2foRKSzVyPUiuOVA6QDFizszN M1jWc3NCVkeHUh?=
LB1047-RCC NEXBUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnCbWdKSzVyPUiuOVIzOTJizszN NH[5RnVUSU6JRWK=
NCI-H520 NHXoOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTHWYZKSzVyPUiuOlIyPTdizszN M4Do[nNCVkeHUh?=
SW954 M3[xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\zTWM2OD16Lk[5O|g3KM7:TR?= NU\0dlZ2W0GQR1XS
TE-6 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XJNWlEPTB;OD63OVE1OyEQvF2= M{OyenNCVkeHUh?=
D-283MED NU\vSoNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7iR5Z3UUN3ME25MlA3PTN2IN88US=> NVeye45jW0GQR1XS
DBTRG-05MG MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvhTWM2OD17LkC5OlA4KM7:TR?= NHzNS3NUSU6JRWK=
NCI-H446 NX3oPJBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLPdJY{UUN3ME25MlI6PTJ4IN88US=> NFf0RZZUSU6JRWK=
HOS NVL0fWE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrUTY1{UUN3ME25MlM2OTN2IN88US=> NHPlNVBUSU6JRWK=
ES4 NYHoVGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\yfZpkUUN3ME25MlUxPTl3IN88US=> NHnGbWFUSU6JRWK=
EW-13 NVnGPFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jiWGlEPTB;OT64PVA2PSEQvF2= MnW3V2FPT0WU
IST-MES1 NVvwUVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7QTWM2OD17Lkm0OVM1KM7:TR?= MXHTRW5ITVJ?
CAS-1 M3:wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3DTWM2OD17Lkm3OlU6KM7:TR?= M3PyO3NCVkeHUh?=
EM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFyLkGzPVMh|ryP MmDJV2FPT0WU
SW948 NHfiWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrtUXlrUUN3ME2xNE4yQDh{IN88US=> MUPTRW5ITVJ?
OAW-42 NEjCfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\NWIc{UUN3ME2xNE42OjZ5IN88US=> MmjsV2FPT0WU
BE-13 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfQTWM2OD1zMD62OVc3KM7:TR?= MX\TRW5ITVJ?
KU812 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzmZYtKSzVyPUGwMlc{QTFizszN MWLTRW5ITVJ?
SK-MEL-30 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXvUnhKSzVyPUGwMlg6ODFizszN M1fVc3NCVkeHUh?=
A2780 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf2TWM2OD1zMT6wN|A5KM7:TR?= NIO1cm1USU6JRWK=
TGBC24TKB NY[5c|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy3[pdKSzVyPUGxMlA4OzdizszN NHTYZ5NUSU6JRWK=
GOTO M3O2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjTTWM2OD1zMT6yNFg1KM7:TR?= NInLTZFUSU6JRWK=
NCI-H526 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFzLkO4N|ch|ryP M4HQUnNCVkeHUh?=
BHT-101 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFzLkS0OVYh|ryP NGK1eoFUSU6JRWK=
NCI-H1155 NVPNdYNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2na[2lEPTB;MUGuOFk1PyEQvF2= MoDLV2FPT0WU
MCF7 NHnze5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXsTWM2OD1zMT62NVY4KM7:TR?= NHu5b4xUSU6JRWK=
MKN45 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrjWmtwUUN3ME2xNU44QTl|IN88US=> M3mxNXNCVkeHUh?=
MOLT-16 M{TFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PRSmlEPTB;MUGuPVY6OiEQvF2= M2XmVnNCVkeHUh?=
YH-13 M1jVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF{LkCzOFYh|ryP MnvvV2FPT0WU
P12-ICHIKAWA MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3lTJVKSzVyPUGyMlM5PDVizszN NHXHOVNUSU6JRWK=
GR-ST NYrl[ZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTuTWM2OD1zMj61Nlk2KM7:TR?= M1z3WXNCVkeHUh?=
CAKI-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2TGlEPTB;MUKuO|kyKM7:TR?= MWXTRW5ITVJ?
LXF-289 MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKwTWM2OD1zMz6wPFM2KM7:TR?= NW\VVIlKW0GQR1XS
MHH-PREB-1 NFjUbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7NTWM2OD1zMz6yO|A1KM7:TR?= MWPTRW5ITVJ?
EW-16 NF;wRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF|LkOxPFch|ryP MmPQV2FPT0WU
NCI-H82 NELNfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[5TWM2OD1zMz60NVk2KM7:TR?= M1PRXHNCVkeHUh?=
MMAC-SF NGLpS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTiTWM2OD1zMz60OVQ4KM7:TR?= MWrTRW5ITVJ?
COLO-684 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jpU2lEPTB;MUOuOVMyQCEQvF2= NFPYSWNUSU6JRWK=
QIMR-WIL M2\MdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGniWGJKSzVyPUGzMlgyODlizszN MkjUV2FPT0WU
NB69 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfjWHN4UUN3ME2xN{46QDZ6IN88US=> NVXQZlJqW0GQR1XS
NCI-H2291 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF2LkS0OVMh|ryP NELHblhUSU6JRWK=
MKN7 NGPYUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3GTWM2OD1zND62Olc3KM7:TR?= MV3TRW5ITVJ?
HDLM-2 M2\GZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF3LkGyPFYh|ryP NV\DVmdFW0GQR1XS
A253 NXzKbHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NICwWVVKSzVyPUG1MlM5PjlizszN NF;SXVJUSU6JRWK=
SK-LU-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TMeWlEPTB;MUWuPVA6PCEQvF2= MnLjV2FPT0WU
MEG-01 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:3[2lEPTB;MUWuPVExPyEQvF2= Moi2V2FPT0WU
SK-N-DZ NIeyWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\JfZpKSzVyPUG1Mlk{PzZizszN NWDCbJhoW0GQR1XS
H4 NE\ISJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXRUXV{UUN3ME2xOk4xQDhizszN MV\TRW5ITVJ?
LU-65 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[5UmlEPTB;MU[uN|M5PCEQvF2= MX3TRW5ITVJ?
NCI-H1048 NVnOUmxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF4LkWxOlUh|ryP NGSwZmpUSU6JRWK=
LCLC-97TM1 NWHlVZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnSdmNxUUN3ME2xOk42QDh7IN88US=> NHLSXZhUSU6JRWK=
CAL-120 NUDtN3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvBUWRKSzVyPUG2Mlk5PzlizszN NGjtXXJUSU6JRWK=
LU-134-A M4\oSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF5LkOzPVEh|ryP M3:1WHNCVkeHUh?=
SK-MEL-1 NYL1bo9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF5LkexNlch|ryP MXvTRW5ITVJ?
NCI-H69 NGHrRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF5LkmzNFch|ryP M4nae3NCVkeHUh?=
MC116 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi0cWg3UUN3ME2xO{46PzVizszN NXO5RVE2W0GQR1XS
UMC-11 NUP0[5llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjJTol[UUN3ME2xPE4yPzh6IN88US=> NXzteHczW0GQR1XS
HCC1395 M3L6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\vNHFPUUN3ME2xPE41OzBzIN88US=> M1vNdHNCVkeHUh?=
no-10 M3qxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImzdYFKSzVyPUG4MlY{QDhizszN M3HUUXNCVkeHUh?=
NY NXfaZZhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\JTWM2OD1zOT6wPFA6KM7:TR?= M4nuVXNCVkeHUh?=
OS-RC-2 NHPTbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXLTWM2OD1zOT6xNlUzKM7:TR?= NVvie4NiW0GQR1XS
D-423MG NEO3[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS0TWM2OD1zOT6zPVUzKM7:TR?= NV7ENXNHW0GQR1XS
LC-2-ad MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfWTWM2OD1zOT63OlEzKM7:TR?= NFW5TIhUSU6JRWK=
DU-4475 NHjlcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF7Lki4OVIh|ryP NWrqVJhKW0GQR1XS
YKG-1 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTkTWM2OD1zOT65OlIh|ryP M160ZnNCVkeHUh?=
HCC1569 NWPEc2huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPEUodKSzVyPUKwMlI3OjRizszN NEjZN5pUSU6JRWK=
TYK-nu NHnmXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnSXHk4UUN3ME2yNE4zQDR5IN88US=> MV;TRW5ITVJ?
DEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\jTWlEPTB;MkCuPVgxQCEQvF2= NI\wVnVUSU6JRWK=
MHH-ES-1 NIXtbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHOTWM2OD1{MT6zOVk4KM7:TR?= M3:0cXNCVkeHUh?=
KARPAS-299 NIHhS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHiV2JYUUN3ME2yNU42OjlizszN MXXTRW5ITVJ?
CTV-1 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vkdmlEPTB;MkGuOlE4OiEQvF2= Mnf4V2FPT0WU
NCI-H2452 NUfod|NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ{Lk[2O|ch|ryP NITvSmhUSU6JRWK=
D-566MG NH7FRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\kTWM2OD1{Mj63OlAyKM7:TR?= M3\Ec3NCVkeHUh?=
EFO-27 NVvQNJJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jCdGlEPTB;MkOuNFY2OSEQvF2= NXS0Z5d4W0GQR1XS
NCI-H596 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvOSXF{UUN3ME2yN{45PTJ5IN88US=> NXzkPHZMW0GQR1XS
KS-1 NGXQcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G2WGlEPTB;MkSuNlc2QSEQvF2= M3PMWXNCVkeHUh?=
8305C M2n0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q4ZmlEPTB;MkSuOFA1PSEQvF2= NGDqSGJUSU6JRWK=
A427 NYTWT2VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvxXXVDUUN3ME2yOU4xOzJ|IN88US=> M1r1enNCVkeHUh?=
COLO-800 NGPUUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ3LkGwOlEh|ryP NVXzNpluW0GQR1XS
SJRH30 NUftXpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ3LkO5NFgh|ryP NIDydJBUSU6JRWK=
MEL-HO MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH5O3RKSzVyPUK1MlQ{OTlizszN NF7jWVRUSU6JRWK=
FTC-133 M1HCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwNXhKSzVyPUK1MlgyQDZizszN M1vKS3NCVkeHUh?=
SF295 Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\JUoVKSzVyPUK2MlI6PiEQvF2= NIXE[ZZUSU6JRWK=
SW1710 NXjON|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rxdmlEPTB;Mk[uOFEzOyEQvF2= NG\xb3JUSU6JRWK=
EFM-19 M3HnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf0SY5XUUN3ME2yOk45OTR3IN88US=> M2DMbnNCVkeHUh?=
NB10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VXJhKSzVyPUK4MlIzQTdizszN M2HoXXNCVkeHUh?=
TK10 NGLIUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ6LkKzPVkh|ryP NHXXTJFUSU6JRWK=
D-502MG M1;0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rJOGlEPTB;MkiuOEDPxE1? M3jocXNCVkeHUh?=
EW-18 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTsVYlvUUN3ME2yPE41Ozh4IN88US=> M17mTHNCVkeHUh?=
VMRC-RCZ NGXtTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLDdZljUUN3ME2yPE46PDFizszN MkLPV2FPT0WU
Ca9-22 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfkVWN6UUN3ME2yPU41PTV5IN88US=> NVTNfVZNW0GQR1XS
KYSE-70 NXzhOYVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ7LkW3PFYh|ryP MXXTRW5ITVJ?
A101D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLXeYh1UUN3ME2yPU43PDd{IN88US=> NFzmO5pUSU6JRWK=
WM-115 M2PMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5TWM2OD1{OT63OlA4KM7:TR?= NIDteHJUSU6JRWK=
HCC2157 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHueGpKSzVyPUK5Mlg5ODdizszN M2i5cnNCVkeHUh?=
TE-9 M3LIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT5cJBKSzVyPUK5Mlg5PjVizszN M{XQR3NCVkeHUh?=
K-562 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXIXINlUUN3ME2zNE4xQTN|IN88US=> NXjJVZB6W0GQR1XS
SN12C M3\uWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnPSXZZUUN3ME2zNE4yPDJ4IN88US=> MXXTRW5ITVJ?
ESS-1 NXLDS4o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD5V29yUUN3ME2zNE41PzV7IN88US=> MXXTRW5ITVJ?
K5 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNyLke2OEDPxE1? NH7ac3FUSU6JRWK=
J82 NYj0fJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS3TWM2OD1|MT6wPFk4KM7:TR?= NETnUHZUSU6JRWK=
HOP-92 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNzLkGxNVEh|ryP M{XrVHNCVkeHUh?=
NCI-H2228 NGDneXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\sdGlEPTB;M{GuN|I6PiEQvF2= MmjiV2FPT0WU
OCI-AML2 NFHHUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnznTWM2OD1|MT6zOlEh|ryP NHnO[YZUSU6JRWK=
NCI-SNU-5 NFjnO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrkU4xKSzVyPUOxMlgyOzdizszN NHvhRXJUSU6JRWK=
A3-KAW NXnDUJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HaS2lEPTB;M{GuPVI1OyEQvF2= NWTRRpB3W0GQR1XS
LCLC-103H MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXUZXVNUUN3ME2zNk4xOTdzIN88US=> MXnTRW5ITVJ?
KY821 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN{Lk[4PFQh|ryP NHrxfGxUSU6JRWK=
JVM-2 M{HTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rhWmlEPTB;M{KuPVA4QSEQvF2= NYr3UmdWW0GQR1XS
Mo-T MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m1fmlEPTB;M{OuNVAxPSEQvF2= NHTU[WFUSU6JRWK=
IA-LM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDRdnBRUUN3ME2zN{4zPzVizszN NH;mXJZUSU6JRWK=
C8166 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN|LkOxPVIh|ryP MoG3V2FPT0WU
TCCSUP MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi5flVKSzVyPUOzMlQ{ODdizszN M3fPUnNCVkeHUh?=
JEG-3 NHywbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTXT4dKSzVyPUOzMlQ4PjhizszN MWnTRW5ITVJ?
MS-1 NYXTfnZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnnVYNDUUN3ME2zN{42PTVzIN88US=> NEHCb|VUSU6JRWK=
NCI-H1304 NX7neFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\PcIk6UUN3ME2zN{42PzJ3IN88US=> NV[wNos2W0GQR1XS
Ramos-2G6-4C10 NWD1eIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfMV5hTUUN3ME2zOE4xOzN3IN88US=> NYO4XmkyW0GQR1XS
MDA-MB-453 M4XWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\tXJJKSzVyPUO0MlY{QTVizszN NYG3em96W0GQR1XS
KYSE-520 NXrpXJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHUOnJKSzVyPUO0MlcyQDFizszN NIXWNm9USU6JRWK=
SW900 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrNUmpIUUN3ME2zOE45OTF3IN88US=> MUDTRW5ITVJ?
HCC2998 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTN3LkG1Nlkh|ryP NY[5SpZyW0GQR1XS
A2058 NFSzb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLzT5VKSzVyPUO1MlYxPjFizszN Mn35V2FPT0WU
OVCAR-3 NUe0Nm5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fFdmlEPTB;M{[uNlA1PSEQvF2= NWK5dpFMW0GQR1XS
MOLT-4 NUPCOYQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN4LkKyPVQh|ryP MmSxV2FPT0WU
CAPAN-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DESmlEPTB;M{[uOFY6QSEQvF2= M3y0OnNCVkeHUh?=
SCC-9 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN5LkSwNlch|ryP NWrPVotbW0GQR1XS
SF268 M{LscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7VTWM2OD1|OD6zOFM{KM7:TR?= MWfTRW5ITVJ?
HGC-27 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELBTnpKSzVyPUO4MlM4OTFizszN NUjQ[lBEW0GQR1XS
DOHH-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjkbphJUUN3ME2zPE44OTV6IN88US=> MV\TRW5ITVJ?
KE-37 M3\UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTN6Lkm4Nlgh|ryP MnrOV2FPT0WU
MOLT-13 NV;G[nZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN7LkK1NFIh|ryP NH\rTJJUSU6JRWK=
ES1 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTN7LkO4OUDPxE1? Mn\IV2FPT0WU
SK-OV-3 NEf5VItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLMPFl5UUN3ME2zPU46PjR|IN88US=> Ml63V2FPT0WU
SNU-449 NVq4e3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRyLkC3OlQh|ryP MnrQV2FPT0WU
KYSE-510 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRyLkGyPVUh|ryP MmC5V2FPT0WU
HL-60 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjTcYZKSzVyPUSwMlk4QDNizszN MVfTRW5ITVJ?
DJM-1 NIj3bo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33zdmlEPTB;NECuPVc6QSEQvF2= Mm\HV2FPT0WU
TGBC11TKB M3rSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXrZ2lKSzVyPUSxMlA6OjZizszN NUDJV3dtW0GQR1XS
U-2-OS M2fUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PGbWlEPTB;NEKuNlY1OSEQvF2= Ml3XV2FPT0WU
NCI-H2030 NHv4OJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTR{LkSzOlgh|ryP M2LxfnNCVkeHUh?=
LU-135 NFzQd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UT3ZKSzVyPUSyMlU1PDdizszN MmW5V2FPT0WU
ZR-75-30 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXm[mNKSzVyPUSzMlA1QTNizszN Moe3V2FPT0WU
GT3TKB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXzUmhMUUN3ME20N{4zPjd7IN88US=> NFXCV21USU6JRWK=
RPMI-2650 NWXoTlhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jKRWlEPTB;NEOuO|gyPiEQvF2= MlniV2FPT0WU
SAS NVfvWJRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR|Lkm1N|Qh|ryP M3vWd3NCVkeHUh?=
MDA-MB-231 NVLpcZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PlWmlEPTB;NEOuPVYxQSEQvF2= Mn[wV2FPT0WU
JVM-3 M4faSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR2LkC1N|Mh|ryP NEnUS4RUSU6JRWK=
COLO-320-HSR M1m2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TmVGlEPTB;NESuOVY{OyEQvF2= M{O2b3NCVkeHUh?=
SNB75 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXTTm5DUUN3ME20OE43OTB3IN88US=> NYXHb5RFW0GQR1XS
NCI-H441 NGjQT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTR2LkmzNlgh|ryP MWTTRW5ITVJ?
HCT-116 NXrod5RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjEZmpNUUN3ME20OE46QDZ6IN88US=> NWGwflk6W0GQR1XS
NCI-H226 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLmbZRKSzVyPUS1MlY{PjhizszN MXLTRW5ITVJ?
CAL-33 NV3zRYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\6UGlEPTB;NEWuPVIyPyEQvF2= NF3ud|BUSU6JRWK=
NCI-H1437 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DQXGlEPTB;NE[uN|IyKM7:TR?= MUfTRW5ITVJ?
HCC1187 M{HsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rFVWlEPTB;NE[uOFI2PSEQvF2= NIfJPIJUSU6JRWK=
NUGC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK0UZpKSzVyPUS2MlU4ODlizszN MYTTRW5ITVJ?
T98G NYTIPHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLmTWM2OD12Nz61OFch|ryP MofrV2FPT0WU
OVCAR-8 M4XIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Py[2lEPTB;NEeuOlg{KM7:TR?= NV25eppNW0GQR1XS
LB2241-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jYemlEPTB;NEeuO|I4KM7:TR?= MoPqV2FPT0WU
NCI-H358 M3nHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR6LkGxOVIh|ryP NIL6UGlUSU6JRWK=
PANC-08-13 NXPzR5RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7hNVhlUUN3ME20PE4yQDV|IN88US=> NHr4dlZUSU6JRWK=
KP-N-YN NW\BU4hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnLNVJ7UUN3ME20PE4zOTB{IN88US=> NIewfnVUSU6JRWK=
NCI-H1755 NVHYOFBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDjTWM2OD12OD6yO|I3KM7:TR?= M3G4ZnNCVkeHUh?=
NCI-N87 NXTVNG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR6LkK5PVEh|ryP MnHRV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
+ Expand

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
+ Expand
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Formulation: Prepared in sterile fashion
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of PD173074(S1264) in vivo?

  • Answer:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products4

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID